baseline
DESCRIPTION
A. Baseline. On-treatment. 56% decrease in pS6 staining. B. C. 30% decrease SUVmax in perihepatic disease. CA125 Response Observed. - PowerPoint PPT PresentationTRANSCRIPT
A
Baseline On-treatment
56% decrease in pS6 staining
B30% decrease SUVmax in perihepatic disease
CCA125 Response Observed